Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis

Wei Zhang, Xiaowei Chen, Ling Huang, Ning Lu, Lei Zhou, Guojie Wu, Yuguo Chen, Wei Zhang, Xiaowei Chen, Ling Huang, Ning Lu, Lei Zhou, Guojie Wu, Yuguo Chen

Abstract

Severe sepsis has a high fatality rate, but no clinical indices for prognosis have been established. In recent years, the renin-angiotensin system (RAS) has received considerable attention. However, clinical data on RAS are inconsistent. Therefore, the aim of the present study was to assess the significance of RAS in the prognosis of sepsis. Blood samples were collected from patients, who met the diagnostic criteria of severe sepsis, on day 1 (D1) and 3 (D3). For each sample, the levels of angiotensin II (AngII), angiotensin-converting enzyme (ACE) and additional indices were measured. Patients were monitored for 28 days. On the D1 of inclusion, the average Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 22.2 and the Sepsis-related Organ Failure Assessment (SOFA) score was 6.1. Logistic regression analysis revealed that mortality-associated variables included the APACHE II score on D1, the SOFA score on D1, high lactic acid levels on D3 and low AngII and ACE levels on D1 and D3. AngII levels (<86.1 ng/ml) on D1 had a sensitivity of 88.2% and specificity of 77.3% for predicting mortality. ACE levels (<39.2 ng/ml) on D1 had a sensitivity of 88.2% and specificity of 72.7% for predicting mortality. These two indices were better than the APACHE II and SOFA scores. Therefore, low expression levels of AngII and ACE are valuable in predicting the mortality of patients with severe sepsis.

Keywords: angiotensin II; angiotensin-converting enzyme; mortality; prognosis; severe sepsis.

Figures

Figure 1
Figure 1
Inclusion of patients. ICU, intensive care unit.
Figure 2
Figure 2
ROC curves of the mortality-associated risk factors. ROC, receiver operating characteristic; AngII, angiotensin II; ACE, angiotensin-converting enzyme; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sepsis-related Organ Failure Assessment; Lac, lactate; D, day.

References

    1. Bone RC. A critical evaluation of new agents for the treatment of sepsis. JAMA. 1991;266:1686–1691.
    1. Hicks P, Cooper DJ Australian and New Zealand Intensive Care Society (ANZICS) Board and Clinical Trials Group Executive Committee. The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Resusc. 2008;10:8.
    1. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units French ICU Group for Severe Sepsis. JAMA. 1995;274:968–974.
    1. Tamion F, Le Cam-Duchez V, Menard JF, Girault C, Coquerel A, Bonmarchand G. Erythropoietin and renin as biological markers in critically ill patients. Crit Care. 2004;8:R328–R335.
    1. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007;112:417–428.
    1. Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion. 2004;4:729–741.
    1. Salgado DR, Rocco JR, Silva E, Vincent JL. Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach? Expert Opin Ther Targets. 2010;14:11–20.
    1. Schmidt C, Höcherl K, Kurt B, Moritz S, Kurtz A, Bucher M. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine. 2010;49:30–38.
    1. Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care. 2009;13:R190.
    1. Yunge M, Petros A. Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child. 2000;82:388–389.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions forsepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874. No authors listed.
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
    1. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference of ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818–824.
    1. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980;68:344–355.
    1. Bone RC, Fischer CJ, Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1989;17:389–393.
    1. Sprung CL, Peduzzi PN, Shatney CH, et al. Impact of encephalopathy on mortality in the sepsis syndrome. Crit Care Med. 1990;18:801–806.
    1. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990;161:982–987.
    1. Clemmer TP, Fischer CJ, Jr, Bone RC, Slotman GJ, Metz CA, Thomas FO. Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1992;20:1395–1401.
    1. Zabolotskikh IB, Musaeva TS, Denisova EA. Validity of APACHE II, APACHE III, SAPS 2, SAPS 3 and SOFA scales in obstetric patients with sepsis. Anesteziol Reanimatol. 2012 Nov-Dec;:55–57.
    1. Chen SJ, Chao TF, Chiang MC, Kuo SC, Chen LY, Yin T, Chen TL, Fung CP. Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Intern Med. 2011;50:871–877.
    1. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881–900.
    1. Lund DD, Brooks RM, Faraci FM, Heistad DD. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol. 2007;293:H3726–H3731.
    1. Yao S, Feng D, Wu Q, Li K, Wang L. Losartan attenuates ventilator-induced lung injury. J Surg Res. 2008;145:25–32.
    1. Wiel E, Pu Q, Leclerc J, et al. Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial injury and hemostasis in rabbit endotoxic shock. Intensive Care Med. 2004;30:1652–1659.
    1. Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Koga H, Noguchi T. Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med. 2009;35:1471–1478.
    1. Almeida WS, Maciel TT, Di Marco GS, Casarini DE, Campos AH, Schor N. Escherichia coli lipopolysaccharide inhibits renin activity in human mesangial cells. Kidney Int. 2006;69:974–980.
    1. Bucher M, Hobbhahn J, Kurtz A. Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med. 2001;29:1750–1755.
    1. Dunn CW, Horton JW. Role of angiotensin II in neonatal sepsis. Circ Shock. 1993;40:144–150.
    1. Graninger M, Marsik C, Dukic T, Wagner OF, Blann AD, Jilma B. Enalapril does not alter adhesion molecule levels in human endotoxemia. Shock. 2003;19:448–451.
    1. Bexelius TS, Blomberg J, Lu YX, et al. Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial. World J Gastrointest Endosc. 2012;4:506–512.
    1. Dong LW, Chang YZ, Tong LJ, Tang J, Su JY, Tang CS. Role of regulatory peptide in pathogenesis of shock. Sci China B. 1994;37:162–169.
    1. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283:1038–1045.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit